Table 1.
The basic characteristics of included randomized clinical trials
| Author | Years of publication | Study type | Country | N (mesh/suture) | Sex ratio (male/female) | Age (total or mesh/suture) | Detail of mesh material | Follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| Asti [21] | 2016 | Prospective trial | Italy | 41/43 | 20/64 | 66/66 | Biological mesh | 24 |
| Crespin [18] | 2016 | Retrospective trial | United States | 110/36 | 34/112 | 61.5 | Biological mesh | 9 |
| Frantzides [14] | 2002 | RCT | United States | 36/36 | NA | 63/58 | Permanent mesh | 30 |
| Granderath [15] | 2005 | RCT | Germany | 50/50 | 62/38 | 48/49 | Permanent mesh | 12 |
| Kamolz [19] | 2002 | Retrospective trial | Austria | 100/100 | 121/79 | 48/50 | Permanent mesh | 12 |
| Oeschager [16, 25] | 2006, 2011 | RCT | United States | 51/57 | 27/81 | 67/64 | Biological mesh | 6/58 |
| Ozmen [22] | 2014 | Prospective trial | Turkey | 31/29 | 34/26 | 41/42 | Permanent mesh | 12 |
| Ringley [23] | 2006 | Prospective trial | United States | 22/22 | 24/20 | 58/52 | Biological mesh | 6 |
| Schmidt [20] | 2014 | Retrospective trial | United States | 38/32 | 29/41 | 51/41 | Biological mesh | 12 |
| Kepenekci [24] | 2007 | Prospective trial | Turkey | 176/335 | 271/240 | 48 | Permanent mesh | 24 |
| Watson [17] and Koetje [26] | 2015 | RCT | Australia | 83/43 | 40/86 | 68/68 | Biological/Permanent mesh | 12 |
RCT randomized controlled trials